Dacepton® (Apomorphine hydrochloride) is used for treatment of movement disorders (“on-off” phenomena) in patients with Parkinson’s disease and who cannot be effectively treated using oral anti-Parkinson medicine.
Apomorphine is the strongest clinically available dopamine agonist and belongs to the pharmacological class of anti-Parkinson medicine. The effect of apomorphine unfolds through direct stimulation of dopamine receptors in the central nervous system. A rapid onset action of apomorphine is achieved through subcutaneous administration.
Learn more: www.dacepton.com